Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Although most patients with myelofibrosis (MF) derive benefit from ruxolitinib, some are refractory, have a suboptimal response, or quickly lose their response. To identify genes that may predict response to ruxolitinib, we performed targeted next-generation sequencing (NGS) of a panel of 28 genes r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Patel, Keyur P., Newberry, Kate J., Luthra, Rajyalakshmi, Jabbour, Elias, Pierce, Sherry, Cortes, Jorge, Singh, Rajesh, Mehrotra, Meenakshi, Routbort, Mark J., Luthra, Madan, Manshouri, Taghi, Santos, Fabio P., Kantarjian, Hagop, Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2015
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528066/
https://ncbi.nlm.nih.gov/pubmed/26124496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-633404
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars